Volume : 11, Issue : 01, January – 2024
Title:
THE IMPACT OF DAPAGLIFLOZIN ON URINE ALBUMIN EXCRETION IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES: A PLANNED ANALYSIS FROM THE DAPA-CKD TRIAL
Authors :
Dr Muhammad Imran Saeed, Dr Hafiza Ayesha Munir, Dr Amna Ali
Abstract :
Background: Chronic kidney disease (CKD) has a large worldwide health impact, especially when combined with type 2 diabetes. The DAPA-CKD study looked at how dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, affected urine albumin excretion for individuals having CKD who also had type 2 diabetes.
Aim: The primary goal of our prespecified analysis was to evaluate specific effects of dapagliflozin on urinary albumin excretion in a subpopulation of patients with CKD, elucidating its potential benefits in both diabetic and non-diabetic individuals.
Methods: The DAPA-CKD trial was the multicenter, randomized, double-blind study involving patients having CKD, with and without type-2 diabetes. The trial included a prespecified subgroup analysis focusing on urinary albumin excretion. Individuals were randomly randomized to receive dapagliflozin or a placebo, and the effect on urine albumin excretion was measured over a set time period.
Results: The study found a substantial reduction in urine albumin excretion in participants treated with dapagliflozin compared to the placebo group, regardless of type 2 diabetes. Subgroup analyses further explored variations in response among diabetic and non-diabetic individuals, providing valuable insights into the differential effects of dapagliflozin in these subpopulations.
Conclusion: Dapagliflozin demonstrates a promising therapeutic effect in reducing urinary albumin excretion in patients having CKD, irrespective of their diabetic status. Those results underscore potential of SGLT2 inhibitors as a valuable addition to the treatment armamentarium for individuals with CKD, addressing a critical aspect of renal damage. Further research is warranted to elucidate the long-term implications and mechanisms underlying these observed effects.
Keywords: Dapagliflozin, chronic kidney disease, type-2 diabetes, urinary albumin excretion, SGLT2 inhibitor, DAPA-CKD trial.
Cite This Article:
Please cite this article in press Muhammad Imran Saeed et al., The Impact Of Dapagliflozin On Urine Albumin Excretion In Patients With Chronic Kidney Disease And Type 2 Diabetes: A Planned Analysis From The DAPA-CKD Trial, Indo Am. J. P. Sci, 2024; 11 (01).
Number of Downloads : 10
References:
1. Jongs N, Greene T, Chertow GM, McMurray JJ, Langkilde AM, Correa-Rotter R, Rossing P, Sjöström CD, Stefansson BV, Toto RD, Wheeler DC. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. The lancet Diabetes & endocrinology. 2021 Nov 1;9(11):755-66.
2. Provenzano M, Puchades MJ, Garofalo C, Jongs N, D’Marco L, Andreucci M, De Nicola L, Gorriz JL. Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial. Journal of the American Society of Nephrology. 2022 Aug 1;33(8):1569-80.
3. Cherney DZ, Dekkers CC, Barbour SJ, Cattran D, Gafor AH, Greasley PJ, Laverman GD, Lim SK, Di Tanna GL, Reich HN, Vervloet MG. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. The Lancet Diabetes & Endocrinology. 2020 Jul 1;8(7):582-93.
4. Heerspink HJ, Jongs N, Chertow GM, Langkilde AM, McMurray JJ, Correa-Rotter R, Rossing P, Sjöström CD, Stefansson BV, Toto RD, Wheeler DC. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. The lancet Diabetes & endocrinology. 2021 Nov 1;9(11):743-54.
5. van Ruiten CC, van der Aart‐van der Beek AB, IJzerman RG, Nieuwdorp M, Hoogenberg K, van Raalte DH, Heerspink HJ. Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: a prespecified secondary analysis of a randomized controlled clinical trial. Diabetes, Obesity and Metabolism. 2021 Aug;23(8):1851-8.
6. Zelniker TA, Raz I, Mosenzon O, Dwyer JP, Heerspink HH, Cahn A, Goodrich EL, Im K, Bhatt DL, Leiter LA, McGuire DK. Effect of dapagliflozin on cardiovascular outcomes according to baseline kidney function and albuminuria status in patients with type 2 diabetes: a prespecified secondary analysis of a randomized clinical trial. JAMA cardiology. 2021 Jul 1;6(7):801-10.
7. Eickhoff MK, Olsen FJ, Frimodt-Møller M, Diaz LJ, Faber J, Jensen MT, Rossing P, Persson F. Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria–A double blind randomized placebo-controlled crossover trial. Journal of Diabetes and its Complications. 2020 Jul 1;34(7):107590.
8. van der Aart‐van der Beek AB, Apperloo E, Jongs N, Rouw DB, Sjöström CD, Friedli I, Johansson L, van Raalte DH, Hoogenberg K, Heerspink HJ. Albuminuria‐lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross‐over clinical study. Diabetes, Obesity and Metabolism. 2023 Jun;25(6):1758-68.
9. Sen T, Scholtes R, Greasley PJ, Cherney DZ, Dekkers CC, Vervloet M, Danser AH, Barbour SJ, Karlsson C, Hammarstedt A, Li Q. Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND. Diabetes, Obesity and Metabolism. 2022 Aug;24(8):1578-87.
10. Heerspink HJ, Chertow GM, Jongs N, Correa-Rotter R, Rossing P, Sjöström CD, Langkilde AM. Effects of Dapagliflozin in People without Diabetes and with Microalbuminuria. Clinical Journal of the American Society of Nephrology. 2022 Nov 1;17(11):1665-8.
11. Wheeler DC, Stefánsson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJ, Correa-Rotter R, Rossing P, Toto RD, Sjöström CD. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. The lancet Diabetes & endocrinology. 2021 Jan 1;9(1):22-31.
12. Mårup FH, Thomsen MB, Birn H. Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial. Clinical Kidney Journal. 2023 Sep 26:sfad249.
13. Scholtes RA, Muskiet MH, van Baar MJ, Hesp AC, Greasley PJ, Karlsson C, Hammarstedt A, Arya N, van Raalte DH, Heerspink HJ. Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT trial. Diabetes Care. 2021 Feb 1;44(2):440-7.
14. Lazzaroni E, Lunati ME, Montefusco L, Pastore I, Chebat E, Cimino V, Morpurgo PS, Muratori M, Plebani L, Bolla A, Rossi A. Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study. Pharmacological Research. 2022 Sep 1;183:106374.
15. Wu Z, He X, Xia S, Xiao X, Chen J, Li L. Relationship between dapagliflozin and urinary albumin-to-creatinine ratio in patients with diabetes mellitus and cardiovascular disease: an observational study. Cardiology Plus. 2023 Dec 19:10-97.
16. Shibata R, Taguchi K, Kaida Y, Fukami K. Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus. Clinical and Experimental Nephrology. 2023 Jan;27(1):44-53.
17. Suijk DL, van Baar MJ, van Bommel EJ, Iqbal Z, Krebber MM, Vallon V, Touw D, Hoorn EJ, Nieuwdorp M, Kramer MM, Joles JA. SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function. Clinical Journal of the American Society of Nephrology. 2022 May 1;17(5):663-71.
18. Iijima Y, Nakayama M, Miwa T, Yakou F, Tomiyama H, Shikuma J, Ito R, Tanaka A, Manda N, Odawara M. Nephroprotective Effects of Dapagliflozin in Patients with Type 2 Diabetes. Internal Medicine. 2023 Mar 1;62(5):681-8.
19. Mosenzon O, Wiviott SD, Heerspink HJ, Dwyer JP, Cahn A, Goodrich EL, Rozenberg A, Schechter M, Yanuv I, Murphy SA, Zelniker TA. The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58. Diabetes Care. 2021 Aug 1;44(8):1805-15.
20. Mori D, Kobayashi M, Wada M, Tokuchi M, Misegawa S, Saito R, Nomi H, Haga R, Nagatoya K, Yamauchi A. Effect of Dapagliflozin on Serum Uric Acid Levels in Patients with Advanced Chronic Kidney Disease. Internal Medicine. 2023:1828-23.
21. Iwata Y, Notsu S, Kawamura Y, Mitani W, Tamai S, Morimoto M, Yamato M. The effect of dapagliflozin on uric acid excretion and serum uric acid level in advanced CKD. Scientific Reports. 2023 Mar 24;13(1):4849.
22. Kinguchi S, Wakui H, Ito Y, Kondo Y, Azushima K, Osada U, Yamakawa T, Iwamoto T, Yutoh J, Misumi T, Yasuda G. Relationship between basal sodium intake and the effects of dapagliflozin in albuminuric diabetic kidney disease. Scientific Reports. 2021 Jan 13;11(1):951.
23. Yoshihara F, Imazu M, Sakuma I, Hiroi Y, Hara H, Okazaki O, Ishiguro C, Izumi C, Noguchi T, Shiraiwa T, Nishioka N. DAPagliflozin for the attenuation of albuminuria in Patients with hEaRt failure and type 2 diabetes (DAPPER study): a multicentre, randomised, open-label, parallel-group, standard treatment-controlled trial. eClinicalMedicine. 2023 Dec 1;66.
24. Provenzano M, Jongs N, Vart P, Stefánsson BV, Chertow GM, Langkilde AM, McMurray JJ, Correa-Rotter R, Rossing P, Sjöström CD, Toto RD. The kidney protective effects of the sodium–glucose cotransporter-2 inhibitor, dapagliflozin, are present in patients with CKD treated with mineralocorticoid receptor antagonists. Kidney International Reports. 2022 Mar 1;7(3):436-43.
25. Lieverse TT, Puchades MJ, Mulder UD, Provenzano M, Krenning G, Jongs N, Wink SE, Slart RH, Andreucci M, D’Marco L, De Nicola L. Glomerular and tubular effects of dapagliflozin, eplerenone and their combination in patients with chronic kidney disease: A post‐hoc analysis of the ROTATE‐3 study. Diabetes, Obesity and Metabolism. 2023 Nov 5.